Tuesday, July 11, 2017 12:11:42 PM
The Protalix corporate presentation presented Amicus's Galafold (Migalastat) as a competitor as this was already approved by the EU in 2016. So not unexpected to see the FDA albeit somewhat delayed, following-suit.
Also not particularly concerned with this as Galafold (again as mentioned on the Protalix corporate presentation) is relevant only to about 30% of the Fabry population, i.e. those with amenable mutations. This is because Galafold's job is to bind to particular forms of mis-folded alpha-galactosidase A, then once bound chaperones the relevant amenable a-GalA into the lysosome to help carry-out it's function there. Not only is this relevant only to amenable mutations, but also only works effectively in severe patients.
By comparison, Protalix's Pegunigalsidase (PRX-102), is the actual enzyme that the the patient's need and therefore is open for use for the total Fabry population. Also it has an active time-frame of 14 days, compared to Fabryzyme's 1/2 a day.
Galafold by comparison has to be taken once every 2 days. And it's effective elimination half-life is 3 - 5 hours after dosing. Not exactly a great drug.
So dependent on PRX-102 approval it will be a choice between:
1. Fabryzyme: Relevant to the total Fabry population, but incredibly expensive and very short active time-frame (1/2 day)
2. Galafold: Relevant to about 30% of the Fabry population and has to be taken every 2 days, but with an even shorter elimination half life of 3-5 hours. Convenience of being orally bioavailable.
3. PRX-102: Probably very expensive too and delivered intravenously, but relevant to the total Fabry population, and with a hugely significantly longer active time-frame of 14 days (28 times longer activity than Fabryzyme, and 70 times longer than Galafold).
If Protalix's Pegunigalsidase is approved, it's clear it would be the better treatment.
Recent PLX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 11:02:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 10:56:02 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/17/2024 09:05:17 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/17/2024 09:00:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 11:20:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 10:59:36 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/02/2024 11:36:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 11:56:21 AM
- Levicept Appoints Eliot Forster as CEO • GlobeNewswire Inc. • 11/30/2023 09:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 12:50:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 12:22:32 PM
- Upcoming Earnings Release Paired With Price Target Raise Sends Stock Soaring • AllPennyStocks.com • 10/31/2023 08:40:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/20/2023 10:50:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:50 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM